PF 4634817

Drug Profile

PF 4634817

Alternative Names: PF-04634817; PF-46334817; PF4634817

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action CCR2 receptor antagonists; CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic macular oedema; Diabetic nephropathies; Hepatic fibrosis

Most Recent Events

  • 08 Oct 2015 Pfizer terminates a phase II trial in Diabetic macular oedema in USA, Bulgaria, Czech Republic, Hungary, Germany, Israel, Poland, Romania and Moldova (NCT01994291; EudraCT2013-003147-27)
  • 10 Sep 2014 Phase-II clinical trials in Diabetic macular oedema in Moldova (PO)
  • 01 Sep 2014 Pfizer completes a phase II trial in Diabetic nephropathies in Argentina, Australia, Canada, Germany, Hong Kong, Italy, Malaysia, Peru, Poland, Puerto Rico, Romania, South Korea, Spain and USA (NCT01712061; EudraCT2012-003332-23)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top